Fiche centre
CHU de Grenoble
Grenoble — France
Essais liés5clinical trials
VilleGrenoblelocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07570589
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Zanubrutinib | Cancer | Phase 2 | NCT07739459 | ZEN-CLL — Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NOT_YET_RECRUITING |
| Efgartigimod | Myasthénie | Phase 4 | NCT07072988 | OPTIMAGE — Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod | RECRUITING |
| RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | SEP | À vérifier | NCT03900221 | RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | RECRUITING |
| Ocrelizumab Injection [Ocrevus] | SEP | Phase 3 | NCT05999604 | WINDOCRE — Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial | ACTIVE_NOT_RECRUITING |
| REAL MG PRO — Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Roz | Myasthénie | À vérifier | NCT07570589 | REAL MG PRO — Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) | RECRUITING |